Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH trial of triple immune modulation for refractory factor VIII inhibitors in hemophilia A
NL-OMON42326Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, Provacel and recombinant human coagulation factor VIII in hemophilia A, sponsored by University Medical Center Utrecht. Primary endpoint: Eradication of factor VIII inhibitory activity. Planned start Dec 2015; status: withdrawn.
02
Drugs
rituximabProvacelrecombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON42326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42326.